These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3614 related items for PubMed ID: 32877652

  • 1. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators.
    N Engl J Med; 2019 Nov 21; 381(21):1995-2008. PubMed ID: 31535829
    [Abstract] [Full Text] [Related]

  • 6. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD.
    Lancet; 2020 Jul 11; 396(10244):121-128. PubMed ID: 32446323
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Reduced trial committees and investigators.
    Lancet Diabetes Endocrinol; 2022 Jan 11; 10(1):35-45. PubMed ID: 34861154
    [Abstract] [Full Text] [Related]

  • 10. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T, Ferrannini G, Mellbin L, Benson L, Cosentino F, McMurray JJV, Dahlström U, Lund LH, Savarese G.
    J Card Fail; 2022 Jul 11; 28(7):1050-1062. PubMed ID: 35550428
    [Abstract] [Full Text] [Related]

  • 11. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD, Jhund PS, Claggett BL, Dewan P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJV.
    JACC Heart Fail; 2020 Oct 11; 8(10):811-818. PubMed ID: 32653447
    [Abstract] [Full Text] [Related]

  • 12. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M.
    Lancet Diabetes Endocrinol; 2021 Feb 11; 9(2):106-116. PubMed ID: 33357505
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O'Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber L.
    Circ Heart Fail; 2021 Dec 11; 14(12):e008837. PubMed ID: 34802253
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV.
    Circulation; 2021 Jan 26; 143(4):298-309. PubMed ID: 33040613
    [Abstract] [Full Text] [Related]

  • 15. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M.
    Cardiovasc Diabetol; 2019 Oct 04; 18(1):129. PubMed ID: 31585532
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N.
    Circulation; 2021 Feb 09; 143(6):516-525. PubMed ID: 33186500
    [Abstract] [Full Text] [Related]

  • 18. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV.
    JAMA; 2020 Apr 14; 323(14):1353-1368. PubMed ID: 32219386
    [Abstract] [Full Text] [Related]

  • 19. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
    Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E.
    Adv Ther; 2024 Jul 14; 41(7):2826-2844. PubMed ID: 38771475
    [Abstract] [Full Text] [Related]

  • 20. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Fosbøl E, Bruun NE, Videbæk L, Frederiksen PH, Møller JE, Schou M.
    Trials; 2019 Jun 21; 20(1):374. PubMed ID: 31227014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 181.